23andMe: Wojcicki to Regain Control – $305M Bid
Anne Wojcicki’s TTAM has bid $305 million to regain control of 23andMe, effectively sidelining regeneron’s offer and setting the stage for a strategic shift.This bold move could reshape the future of DNA testing and personalized medicine as Wojcicki perhaps reclaims her vision for the genetic analysis company. With Regeneron withdrawing its interest, the focus now firmly rests on Wojcicki’s leadership and the forthcoming changes at 23andMe. read this breaking news from News Directory 3 for the very latest. Discover what’s next as the agreement is finalized.
Anne Wojcicki Poised to Regain Control of 23andMe
Updated June 13, 2025
Anne Wojcicki, co-founder of 23andMe, is on track to regain control of the DNA testing company. Her nonprofit, TTAM, submitted a $305 million bid, surpassing an offer from Regeneron, sources said. This move positions Wojcicki to perhaps steer the future direction of personalized medicine and genetic analysis.
Regeneron, initially interested in acquiring 23andMe, has reportedly backed away after TTAM’s higher bid. The outcome suggests a renewed focus on Wojcicki’s vision for the company, which has become a prominent player in direct-to-consumer genetic testing.
What’s next
The coming weeks will likely involve finalizing the agreement and transitioning leadership.The move could signal new strategies and initiatives for 23andMe under Wojcicki’s renewed control.